Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment

Abstract

An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients' adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiret- roviral treatments. © 2012 Pefura Yone and Kengne, publisher and licensee Dove Medical Press Ltd.